NRG Energy Inc vs ResMed Inc. — how do they compare? NRG Energy Inc trades at $132.3 (market cap $27.55B), while ResMed Inc. trades at $197.45 (market cap $28.81B). The key difference: NRG Energy Inc and ResMed Inc. are close in size by market cap, and NRG Energy Inc pays the higher dividend (1.46%). Which is the better fit depends on your goals.
| NRG | RMD | |
|---|---|---|
Market Cap | $27.55B | $28.81B |
Sector | Utilities | Health |
52-Week High | $184.03 | $293.73 |
52-Week Low | $120.65 | $182.82 |
Enterprise Value | $51.38B | $27.99B |
Dividend Yield | 1.46% | 1.21% |
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $131.60, up 1.93% over 24 hours, with a bearish technical signal despite bullish oscillators. Recent earnings show mixed results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Revenue grew to $30.71 billion in 2025, though net income margin remains thin at 0.74%. Analyst consensus is strongly bullish with a $217.50 price target, supported by institutional buying interest.
The outlook is cautiously optimistic given strong analyst support and strategic positioning for power demand growth, but risks include volatile cash flows, high debt levels, and execution challenges. The stock offers potential upside if earnings momentum improves, yet investors face headwinds from margin pressure and macroeconomic sensitivity.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →